Effie Tozzo

Company: Avilar Therapeutics

Job title: Chief Scientific Officer

Seminars:

ASGPR vs M6PR: Common & Orthogonal Applications for Extracellular Protein Degradation 3:30 pm

Review of two endocytotic cell surface receptors, ASGPR and M6PR, and their uses for degrading soluble circulating and membrane proteins Novel proprietary ligands for ASGPR and M6PR as backbones for ATAC (ASGPR Targeting Chimeras) and MTAC (M6PR Targeting Chimeras) degraders In vitro and in vivo protein degradation studies comparing ATACs vs MTACs and therapeutic implicationsRead more

day: Bootcamp Day